Soon after the onset of the pandemic, several panels of experts in Spanish, European, and American oncology associations recommended the modification of oncological treatments to induce less neutropenia and to consider expanding the indications of Filgrastim (G-CSF) use to patients with intermediate (10–20%) and higher neutropenia risk. Here, CSF3 is linked to neutropenia.